We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App




New Hematology Analyzer Brings High-Standard Reticulocyte Analysis to a Compact Platform

By LabMedica International staff writers
Posted on 03 Mar 2014
A new, reliable, easy-to-use hematology analyzer with integrated PC eliminates manual methods to enhance laboratory productivity while maintaining standardization.

Horiba Medical division of Horiba UK (Northhampton, UK) now offers the new "Pentra XLR compact 5 part DIFF" hematology analyzer, incorporating full reticulocyte parameters to facilitate the investigation and diagnosis of hemopoiesis and anemia. More...
As the latest addition to the Pentra family, the XLR brings Horiba’s gold standard reticulocyte technology with STAT capabilities to a smaller platform. This makes it well suited for space-restricted laboratories or those with a smaller workload, without compromising on quality.

The new, reliable, easy-to-use analyzer with integrated PC eliminates manual methods to enhance laboratory productivity and ensure standardization of reticulocyte count. The Pentra XLR’s large capacity autoloader and ability to process 80 samples per hour, combined with auto rerun, Customized Dilution Ratio (CDR) and automatic validation, all enable a hands-off approach. Users can thus dedicate valuable time to results analysis and more specialised needs.

Providing a high degree of flexibility, the new Pentra XLR has a microsampling system requiring only 53 µl of blood for FBC and 35 µl for full reticulocyte analysis, making it well suited for pediatric or other small samples. The reticulocyte channel utilizes Thiazole Orange technology, providing a full maturity profile in addition to a highly accurate reticulocyte count. It is also compatible with ABX Pentra ML data management, facilitating simple integration into existing systems.
The new Pentra XLR is built on the same proven reticulocyte technology as Horiba’s higher throughput Pentra analyzers, ensuring quality and full compatibility of results and reagents. With three quality control levels for all parameters, this robust and reliable platform also provides complete data traceability on-board and integrated validation, thus enhancing peace of mind also for the user.

“The Pentra XLR enhances laboratory productivity, flexibility and quality, adding value to any hematology laboratory,” said Cleve Wright, Horiba UK; “By incorporating full reticulocyte analytical capabilities, the Pentra XLR delivers high quality detailed analysis for highly accurate patient diagnosis on a compact platform.”

Related Links:

Horiba Medical



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.